Sonoma Pharmaceuticals (NASDAQ:SNOA) Issues Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) posted its quarterly earnings results on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, Zacks reports. Sonoma Pharmaceuticals had a negative net margin of 27.21% and a negative return on equity of 59.58%.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ:SNOA traded down $0.03 during trading on Wednesday, reaching $2.66. 17,810 shares of the stock were exchanged, compared to its average volume of 57,140. Sonoma Pharmaceuticals has a 12-month low of $2.44 and a 12-month high of $9.37. The firm’s 50-day moving average price is $2.69 and its 200 day moving average price is $2.36. The firm has a market cap of $3.56 million, a price-to-earnings ratio of -0.53 and a beta of 1.43.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.